# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
- Reuters
Gilead Sciences exposes a major counterfeiting ring led by Peter Khaim, involving tampered HIV medications resold from New York...
Truist Securities analyst Robyn Karnauskas maintains Gilead Sciences (NASDAQ:GILD) with a Hold and raises the price target f...
FDA grants accelerated approval to Gilead's Livdelzi (seladelpar) for primary biliary cholangitis, offering new treatment o...
Needham analyst Joseph Stringer reiterates Gilead Sciences (NASDAQ:GILD) with a Hold.
- Reuters Citing Co Website
RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform and raises the price target...